RxDoctor Payments Data

Thomas Wells, DO

Gastroenterology · Bowling Green, KYNPI 1386006575

Payments from drug & device makers

$6,590in general payments, 2019–2025

Across 271 payments — averaging $24.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Intuitive Surgical$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$515
  • Regeneron Healthcare Solutions, Inc.$321
  • Takeda Pharmaceuticals U.S.A., Inc.$273
  • Gilead$246
  • plus $2K from 22 others

What the payments were for

  • Travel & lodging$1,75927%
  • Food & beverage$4,81273%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,590 in reported general payments places this provider in the 60th percentile of 207 gastroenterology providers in Kentucky.

See all gastroenterology providers in Kentucky

Medicare billing

Part B allowed, 2024
$126,714
Medicare patients
427
Services billed
3,174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin22$62,893
LinzessLinaclotide17$23,010
Mesalamine17$8,714
Sucralfate16$1,822
Esomeprazole Magnesium65$1,362
Dexlansoprazole DrDexlansoprazole11$1,119
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl54$962
Omeprazole105$727
Dicyclomine Hcl30$632
Pantoprazole Sodium67$567
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl30$481
Ondansetron Hcl21$462
Famotidine45$232
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl13$228
LoperamideLoperamide Hcl12$203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$515$62,89322 claims
AbbVieLinzess$1,888$23,01017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 207 gastroenterology providers in Kentucky.

Other gastroenterology in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →